Investigator-Initiated Trials and Studies

Advancing Medical and Scientific Knowledge in Clinical Research 

In addition to advancing the medical and scientific knowledge of MAPS PBC’s study drugs and/or products, the purpose of the investigator-initiated trial and studies program is to provide support for external clinical research in areas that help discover new opportunities to address unmet medical needs.

Consideration will be given to applications proposing to investigate the following:

  • 3,4-Methylenedioxymethamphetamine (MDMA)

Note: MDMA-AT has not been approved by any regulatory agency. The safety and efficacy of MDMA-AT have not been established for the treatment of PTSD.

To submit your research concept, please visit our online portal:

Please email [email protected] with any questions about our IIT program. Read our  Privacy Policy.

MAPS Public Benefit Corporation

Our Mission
Who We Are
Contact Us
Privacy Policy

Cookie Policy

3141 Stevens Creek Blvd #40547
San Jose, CA 95117

Therapy Education for Healthcare Providers

Our Commitment to Therapy Education


MAPS PBC is a wholly-owned subsidiary of the Multidisciplinary Association for Psychedelic Studies (MAPS). MAPS is a 501(c)(3) non-profit research and educational organization.

Stay Up-to-Date about the MDMA-AT Education Program

You have Successfully Subscribed!